Defining the critical hurdles in cancer immunotherapy

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move i...

Full description

Bibliographic Details
Main Authors:	Fox, Bernard A, Schendel, Dolores J, Butterfield, Lisa H, Aamdal, Steinar, Allison, James P, Ascierto, Paolo Antonio, Atkins, Michael B, Bartunkova, Jirina, Bergmann, Lothar, Berinstein, Neil, Bonorino, Cristina C, Borden, Ernest, Bramson, Jonathan L, Britten, Cedrik M, Cao, Xuetao, Carson, William E, Chang, Alfred E, Characiejus, Dainius, Choudhury, A Raja, Coukos, George, de Gruijl, Tanja, Dillman, Robert O, Dolstra, Harry, Dranoff, Glenn, Durrant, Lindy G, Finke, James H, Galon, Jerome, Gollob, Jared A, Gouttefangeas, Cécile, Grizzi, Fabio, Guida, Michele, Håkansson, Leif, Hege, Kristen, Herberman, Ronald B, Hodi, F Stephen, Hoos, Axel, Huber, Christoph, Hwu, Patrick, Imai, Kohzoh, Jaffee, Elizabeth M, Janetzki, Sylvia, June, Carl H, Kalinski, Pawel, Kaufman, Howard L, Kawakami, Koji, Kawakami, Yutaka, Keilholtz, Ulrich, Khleif, Samir N, Kiessling, Rolf, Kotlan, Beatrix, Kroemer, Guido, Lapointe, Rejean, Levitsky, Hyam I, Lotze, Michael T, Maccalli, Cristina, Maio, Michele, Marschner, Jens-Peter, Mastrangelo, Michael J, Masucci, Giuseppe, Melero, Ignacio, Melief, Cornelius, Murphy, William J, Nelson, Brad, Nicolini, Andrea, Nishimura, Michael I, Odunsi, Kunle, Ohashi, Pamela S, O'Donnell-Tormey, Jill, Old, Lloyd J, Ottensmeier, Christian, Papamichail, Michael, Parmiani, Giorgio, Pawelec, Graham, Proietti, Enrico, Qin, Shukui, Rees, Robert, Ribas, Antoni, Ridolfi, Ruggero, Ritter, Gerd, Rivoltini, Licia, Romero, Pedro J, Salem, Mohamed L, Scheper, Rik J, Seliger, Barbara, Sharma, Padmanee, Shiku, Hiroshi, Singh-Jasuja, Harpreet, Song, Wenru, Straten, Per Thor, Tahara, Hideaki, Tian, Zhigang, van Der Burg, Sjoerd H, von Hoegen, Paul, Wang, Ena, Welters, Marij JP, Winter, Hauke, Withington, Tara, Wolchok, Jedd D, Xiao, Weihua, Zitvogel, Laurence, Zwierzina, Heinz, Marincola, Francesco M, Gajewski, Thomas F, Wigginton, Jon M, Disis, Mary L
Format:	Online
Language:	English
Published:	BioMed Central 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338100/

id	pubmed-3338100
recordtype	oai_dc
spelling	pubmed-33381002012-04-27 Defining the critical hurdles in cancer immunotherapy Fox, Bernard A Schendel, Dolores J Butterfield, Lisa H Aamdal, Steinar Allison, James P Ascierto, Paolo Antonio Atkins, Michael B Bartunkova, Jirina Bergmann, Lothar Berinstein, Neil Bonorino, Cristina C Borden, Ernest Bramson, Jonathan L Britten, Cedrik M Cao, Xuetao Carson, William E Chang, Alfred E Characiejus, Dainius Choudhury, A Raja Coukos, George de Gruijl, Tanja Dillman, Robert O Dolstra, Harry Dranoff, Glenn Durrant, Lindy G Finke, James H Galon, Jerome Gollob, Jared A Gouttefangeas, Cécile Grizzi, Fabio Guida, Michele Håkansson, Leif Hege, Kristen Herberman, Ronald B Hodi, F Stephen Hoos, Axel Huber, Christoph Hwu, Patrick Imai, Kohzoh Jaffee, Elizabeth M Janetzki, Sylvia June, Carl H Kalinski, Pawel Kaufman, Howard L Kawakami, Koji Kawakami, Yutaka Keilholtz, Ulrich Khleif, Samir N Kiessling, Rolf Kotlan, Beatrix Kroemer, Guido Lapointe, Rejean Levitsky, Hyam I Lotze, Michael T Maccalli, Cristina Maio, Michele Marschner, Jens-Peter Mastrangelo, Michael J Masucci, Giuseppe Melero, Ignacio Melief, Cornelius Murphy, William J Nelson, Brad Nicolini, Andrea Nishimura, Michael I Odunsi, Kunle Ohashi, Pamela S O'Donnell-Tormey, Jill Old, Lloyd J Ottensmeier, Christian Papamichail, Michael Parmiani, Giorgio Pawelec, Graham Proietti, Enrico Qin, Shukui Rees, Robert Ribas, Antoni Ridolfi, Ruggero Ritter, Gerd Rivoltini, Licia Romero, Pedro J Salem, Mohamed L Scheper, Rik J Seliger, Barbara Sharma, Padmanee Shiku, Hiroshi Singh-Jasuja, Harpreet Song, Wenru Straten, Per Thor Tahara, Hideaki Tian, Zhigang van Der Burg, Sjoerd H von Hoegen, Paul Wang, Ena Welters, Marij JP Winter, Hauke Withington, Tara Wolchok, Jedd D Xiao, Weihua Zitvogel, Laurence Zwierzina, Heinz Marincola, Francesco M Gajewski, Thomas F Wigginton, Jon M Disis, Mary L Commentary Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. BioMed Central 2011-12-14 /pmc/articles/PMC3338100/ /pubmed/22168571 http://dx.doi.org/10.1186/1479-5876-9-214 Text en Copyright ©2011 Fox et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Fox, Bernard A Schendel, Dolores J Butterfield, Lisa H Aamdal, Steinar Allison, James P Ascierto, Paolo Antonio Atkins, Michael B Bartunkova, Jirina Bergmann, Lothar Berinstein, Neil Bonorino, Cristina C Borden, Ernest Bramson, Jonathan L Britten, Cedrik M Cao, Xuetao Carson, William E Chang, Alfred E Characiejus, Dainius Choudhury, A Raja Coukos, George de Gruijl, Tanja Dillman, Robert O Dolstra, Harry Dranoff, Glenn Durrant, Lindy G Finke, James H Galon, Jerome Gollob, Jared A Gouttefangeas, Cécile Grizzi, Fabio Guida, Michele Håkansson, Leif Hege, Kristen Herberman, Ronald B Hodi, F Stephen Hoos, Axel Huber, Christoph Hwu, Patrick Imai, Kohzoh Jaffee, Elizabeth M Janetzki, Sylvia June, Carl H Kalinski, Pawel Kaufman, Howard L Kawakami, Koji Kawakami, Yutaka Keilholtz, Ulrich Khleif, Samir N Kiessling, Rolf Kotlan, Beatrix Kroemer, Guido Lapointe, Rejean Levitsky, Hyam I Lotze, Michael T Maccalli, Cristina Maio, Michele Marschner, Jens-Peter Mastrangelo, Michael J Masucci, Giuseppe Melero, Ignacio Melief, Cornelius Murphy, William J Nelson, Brad Nicolini, Andrea Nishimura, Michael I Odunsi, Kunle Ohashi, Pamela S O'Donnell-Tormey, Jill Old, Lloyd J Ottensmeier, Christian Papamichail, Michael Parmiani, Giorgio Pawelec, Graham Proietti, Enrico Qin, Shukui Rees, Robert Ribas, Antoni Ridolfi, Ruggero Ritter, Gerd Rivoltini, Licia Romero, Pedro J Salem, Mohamed L Scheper, Rik J Seliger, Barbara Sharma, Padmanee Shiku, Hiroshi Singh-Jasuja, Harpreet Song, Wenru Straten, Per Thor Tahara, Hideaki Tian, Zhigang van Der Burg, Sjoerd H von Hoegen, Paul Wang, Ena Welters, Marij JP Winter, Hauke Withington, Tara Wolchok, Jedd D Xiao, Weihua Zitvogel, Laurence Zwierzina, Heinz Marincola, Francesco M Gajewski, Thomas F Wigginton, Jon M Disis, Mary L
spellingShingle	Fox, Bernard A Schendel, Dolores J Butterfield, Lisa H Aamdal, Steinar Allison, James P Ascierto, Paolo Antonio Atkins, Michael B Bartunkova, Jirina Bergmann, Lothar Berinstein, Neil Bonorino, Cristina C Borden, Ernest Bramson, Jonathan L Britten, Cedrik M Cao, Xuetao Carson, William E Chang, Alfred E Characiejus, Dainius Choudhury, A Raja Coukos, George de Gruijl, Tanja Dillman, Robert O Dolstra, Harry Dranoff, Glenn Durrant, Lindy G Finke, James H Galon, Jerome Gollob, Jared A Gouttefangeas, Cécile Grizzi, Fabio Guida, Michele Håkansson, Leif Hege, Kristen Herberman, Ronald B Hodi, F Stephen Hoos, Axel Huber, Christoph Hwu, Patrick Imai, Kohzoh Jaffee, Elizabeth M Janetzki, Sylvia June, Carl H Kalinski, Pawel Kaufman, Howard L Kawakami, Koji Kawakami, Yutaka Keilholtz, Ulrich Khleif, Samir N Kiessling, Rolf Kotlan, Beatrix Kroemer, Guido Lapointe, Rejean Levitsky, Hyam I Lotze, Michael T Maccalli, Cristina Maio, Michele Marschner, Jens-Peter Mastrangelo, Michael J Masucci, Giuseppe Melero, Ignacio Melief, Cornelius Murphy, William J Nelson, Brad Nicolini, Andrea Nishimura, Michael I Odunsi, Kunle Ohashi, Pamela S O'Donnell-Tormey, Jill Old, Lloyd J Ottensmeier, Christian Papamichail, Michael Parmiani, Giorgio Pawelec, Graham Proietti, Enrico Qin, Shukui Rees, Robert Ribas, Antoni Ridolfi, Ruggero Ritter, Gerd Rivoltini, Licia Romero, Pedro J Salem, Mohamed L Scheper, Rik J Seliger, Barbara Sharma, Padmanee Shiku, Hiroshi Singh-Jasuja, Harpreet Song, Wenru Straten, Per Thor Tahara, Hideaki Tian, Zhigang van Der Burg, Sjoerd H von Hoegen, Paul Wang, Ena Welters, Marij JP Winter, Hauke Withington, Tara Wolchok, Jedd D Xiao, Weihua Zitvogel, Laurence Zwierzina, Heinz Marincola, Francesco M Gajewski, Thomas F Wigginton, Jon M Disis, Mary L Defining the critical hurdles in cancer immunotherapy
author_facet	Fox, Bernard A Schendel, Dolores J Butterfield, Lisa H Aamdal, Steinar Allison, James P Ascierto, Paolo Antonio Atkins, Michael B Bartunkova, Jirina Bergmann, Lothar Berinstein, Neil Bonorino, Cristina C Borden, Ernest Bramson, Jonathan L Britten, Cedrik M Cao, Xuetao Carson, William E Chang, Alfred E Characiejus, Dainius Choudhury, A Raja Coukos, George de Gruijl, Tanja Dillman, Robert O Dolstra, Harry Dranoff, Glenn Durrant, Lindy G Finke, James H Galon, Jerome Gollob, Jared A Gouttefangeas, Cécile Grizzi, Fabio Guida, Michele Håkansson, Leif Hege, Kristen Herberman, Ronald B Hodi, F Stephen Hoos, Axel Huber, Christoph Hwu, Patrick Imai, Kohzoh Jaffee, Elizabeth M Janetzki, Sylvia June, Carl H Kalinski, Pawel Kaufman, Howard L Kawakami, Koji Kawakami, Yutaka Keilholtz, Ulrich Khleif, Samir N Kiessling, Rolf Kotlan, Beatrix Kroemer, Guido Lapointe, Rejean Levitsky, Hyam I Lotze, Michael T Maccalli, Cristina Maio, Michele Marschner, Jens-Peter Mastrangelo, Michael J Masucci, Giuseppe Melero, Ignacio Melief, Cornelius Murphy, William J Nelson, Brad Nicolini, Andrea Nishimura, Michael I Odunsi, Kunle Ohashi, Pamela S O'Donnell-Tormey, Jill Old, Lloyd J Ottensmeier, Christian Papamichail, Michael Parmiani, Giorgio Pawelec, Graham Proietti, Enrico Qin, Shukui Rees, Robert Ribas, Antoni Ridolfi, Ruggero Ritter, Gerd Rivoltini, Licia Romero, Pedro J Salem, Mohamed L Scheper, Rik J Seliger, Barbara Sharma, Padmanee Shiku, Hiroshi Singh-Jasuja, Harpreet Song, Wenru Straten, Per Thor Tahara, Hideaki Tian, Zhigang van Der Burg, Sjoerd H von Hoegen, Paul Wang, Ena Welters, Marij JP Winter, Hauke Withington, Tara Wolchok, Jedd D Xiao, Weihua Zitvogel, Laurence Zwierzina, Heinz Marincola, Francesco M Gajewski, Thomas F Wigginton, Jon M Disis, Mary L
author_sort	Fox, Bernard A
title	Defining the critical hurdles in cancer immunotherapy
title_short	Defining the critical hurdles in cancer immunotherapy
title_full	Defining the critical hurdles in cancer immunotherapy
title_fullStr	Defining the critical hurdles in cancer immunotherapy
title_full_unstemmed	Defining the critical hurdles in cancer immunotherapy
title_sort	defining the critical hurdles in cancer immunotherapy
description	Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.
publisher	BioMed Central
publishDate	2011
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338100/
_version_	1611525219147579392

Defining the critical hurdles in cancer immunotherapy

Similar Items